California Collaborative Network om datagestuurde zorg te bevorderen en de resultaten bij vroege psychose te verbeteren (EPI-CAL)

A prolonged first episode of psychosis (FEP) without adequate treatment is the most consistent predictor of poor clinical and functional outcomes, poor health outcomes and significant economic burden. Team-based "coordinated specialty care" (CSC) for early psychosis (EP) has established effectiveness in promoting clinical and functional recovery. EP treatment programs have expanded rapidly with increased funding across the US without formal coordination of training or implementation. While EP programs share many features, the lack of state and national coordination and data infrastructure limits the capacity for large-scale evaluation or accelerated dissemination of best practices. Based on prior collaborations with 30 California (CA) EP programs and experiences using mobile health (MOBI mHealth) technology to measure individual outcomes in EP care, the UC Davis (UCD) team is uniquely poised to create EPI-CAL, a CA network that will contribute systematically collected outcomes data on 1329 FEP clients per year, from 6 community and 6 university EP clinics, to a national EP network supported by the NIMH EPINET program.

Building on the team's prior work evaluating CA EP programs, EPI-CAL programs will participate in a formative evaluation in Year 1 to define core EP clinical features, intervention targets, and outcomes needed to harmonize network input. A "core battery" based on current measures collected at the sites, the PhenX toolkit and expanded to cover all critical domains, will be installed across the network in Year 2. Core client outcomes and metrics of data use for treatment decisions will be collected using the custom MOBI mHealth data network at the client, program, and state level to allow easy data analysis, interpretation and dissemination. Training and ongoing monitoring will be provided at all EPI-CAL sites to ensure appropriate implementation. EPI-CAL will contribute de-identified data to the national coordinating hub. Using the RE-AIM implementation science framework, the investigators will systematically evaluate the impact of MOBI on EP programs across 5 dimensions: reach, efficacy, adoption, implementation, and maintenance.

To demonstrate the network's research capacity, in the R34 component of this application, the investigators propose to develop and validate a measure of the Duration of Untreated Psychosis (DUP) that is feasible for use in community settings and psychometrically sound. Although DUP is a significant predictor of both short-term CSC treatment response and long-term outcomes for FEP, no measure currently exists that has been rigorously validated and is feasible for use by community providers. The investigators will utilize stakeholder feedback (clients, family members, academic experts and CSC staff) to develop a tool with standardized DUP definitions that includes anchored assessment of psychosis onset and start of treatment. Developing such a tool will allow standardized assessment of this critical moderator of CSC outcomes across the entire EPINET.

FEP (and CHR) individuals receiving early psychosis treatment services at one of the participating sites will be invited to participate in all aspects of the study. Family members/ support persons will be asked to participate in tablet data collection and provide feedback via surveys, interviews and focus groups. EP providers will complete questionnaires and provide feedback via surveys, interviews and focus groups. Stakeholders (e.g. EP program and county administrators, support staff, and local community groups) will participate in focus groups and feedback interviews.

Aim 1: To create a sustainable CA EP network using a core battery of evidence-based measures.To address this aim, the investigators will test the following hypotheses: H1.1: 70% of eligible FEP participants, representative of the target population, and 50% of available family members across the network will enroll and complete baseline (Reach). Client-, provider- and program-level barriers to engagement will be identified through analyses of qualitative data (Reach). H1.2: Clinician use of MOBI over 12 months of care, as measured by MOBI, will be associated with reduced psychotic symptom severity for FEP at 12 months (Efficacy). H1.3: Clinician use of MOBI will be positively associated with reduction in psychotic symptom severity at 24 months and higher patient satisfaction with care (Maintenance).

Aim 2. To develop an integrated data network that provides real-time feedback to improve clinical care and program quality, and contribute de-identified data to the national coordinating hub. The investigators hypothesize that: H2.1: Compared to pre-MOBI, providers will report increased use of data to determine treatment choices after training and using MOBI for 6 months (Adoption); H2.2: Over 12 months, EP providers will use MOBI in direct care to FEP clients for at least 50% of completed assessments (Implementation). Client-, provider- and program-level barriers to implementation will be identified through analyses of qualitative data; H2.3: Exploratory analysis will examine level of clinician expertise and training needed to effectively implement clinician review of FEP participant outcome data using MOBI at 80% of available time points (Adoption).

Aim 3. To develop and validate a novel DUP measure for use in community settings (R34). The investigators hypothesize this new measure will show: H3.1: inter-rater reliability (IRR) between CSC providers and a MA-level assessor with an intra-class coefficient (ICC) of at least .80 for days from initial assessment to DUP start point, days from assessment to DUP end point, and days from start point to end point DUP (total DUP); H3.2: convergent validity, with ICCs of at least .80 between CSC providers and centralized study team assessors using the Symptom Onset in Schizophrenia Inventory (SOS) (reference standard); H3.3: Predictive validity, defined by significant relationships between shorter DUP and greater improvements in functioning and quality of life at 6 and 12 months; H3.4: Feasibility and acceptability to EP providers and clients, with a mean administration time of less than 40 minutes.